The superiority of EGFR TKIs (including gefitinib, erlotinib and afatinib) over conventional chemotherapy in advanced lung adenocarcinoma has been well demonstrated in Phase III randomized trials [3–6, 21]. Here, EGFR is linked to lung adenocarcinoma.